A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147197 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Leiomyoma
Uterine Hemorrhage

Interventions

DRUG: Ulipristal acetate (UPA)
DRUG: Placebo

Sponsor

Allergan